Dr. Patel on Primary and Adaptive Resistance to Immunotherapy in NSCLC

Sandip P. Patel, MD
Published: Thursday, May 24, 2018



Sandip P. Patel, MD, medical oncologist, assistant professor of medicine, University of California, San Diego, discusses primary and adaptive resistance to immunotherapy in non–small cell lung cancer (NSCLC).

Resistance to anti–PD-1 strategies in NSCLC recapitulate some of the data from metastatic melanoma. Oftentimes patients who initially have a response to these strategies, but ultimately develop adaptive resistance have similar downregulation in the human leukocyte antigen and beta-2 microglobulin. These are characteristic in metastatic melanoma as well, says Patel.

However, the majority of patients with NSCLC who benefit from PD-1 inhibition have what is called primary resistance. These are patients who lack the T-cell infiltrate. For these patients, vaccination strategies and other modalities to best determine which therapeutic strategy makes the most sense to inflame an otherwise cold tumor microenvironment will be key. This is one of the biggest areas of research in cancer immunotherapy, in particular for NSCLC, concludes Patel.


Sandip P. Patel, MD, medical oncologist, assistant professor of medicine, University of California, San Diego, discusses primary and adaptive resistance to immunotherapy in non–small cell lung cancer (NSCLC).

Resistance to anti–PD-1 strategies in NSCLC recapitulate some of the data from metastatic melanoma. Oftentimes patients who initially have a response to these strategies, but ultimately develop adaptive resistance have similar downregulation in the human leukocyte antigen and beta-2 microglobulin. These are characteristic in metastatic melanoma as well, says Patel.

However, the majority of patients with NSCLC who benefit from PD-1 inhibition have what is called primary resistance. These are patients who lack the T-cell infiltrate. For these patients, vaccination strategies and other modalities to best determine which therapeutic strategy makes the most sense to inflame an otherwise cold tumor microenvironment will be key. This is one of the biggest areas of research in cancer immunotherapy, in particular for NSCLC, concludes Patel.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x